Literature DB >> 9291716

Olanzapine in PDD.

J P Horrigan, L J Barnhill, H E Courvoisie.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9291716     DOI: 10.1097/00004583-199709000-00007

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


× No keyword cloud information.
  6 in total

Review 1.  The QT interval and psychotropic medications in children: recommendations for clinicians.

Authors:  Paul McNally; Fiona McNicholas; Paul Oslizlok
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-08-29       Impact factor: 4.785

Review 2.  The safety of olanzapine in young children: a systematic review and meta-analysis.

Authors:  Jacqueline Flank; Lillian Sung; Christopher C Dvorak; Wendy Spettigue; L Lee Dupuis
Journal:  Drug Saf       Date:  2014-10       Impact factor: 5.606

Review 3.  Pharmacotherapy of pervasive developmental disorders in children and adolescents.

Authors:  Gabriele Masi
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 4.  Tolerability profile of atypical antipsychotics in children and adolescents.

Authors:  K A Stigler; M N Potenza; C J McDougle
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

5.  Olanzapine in the treatment of pervasive developmental disorders: a case series analysis.

Authors:  Chrissoula Stavrakaki; Ruxandra Antochi; Patricia C Emery
Journal:  J Psychiatry Neurosci       Date:  2004-01       Impact factor: 6.186

Review 6.  Aggression in autism spectrum disorder: presentation and treatment options.

Authors:  Sarah E Fitzpatrick; Laura Srivorakiat; Logan K Wink; Ernest V Pedapati; Craig A Erickson
Journal:  Neuropsychiatr Dis Treat       Date:  2016-06-23       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.